A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 299-305

  Vilar, Eduardo ^a,d   Grünwald, Viktor ^b   Schöffski, Patrick ^b   Singer, Harald ^c   Salazar, Ramon ^a   Iglesias, Jose Luis ^c   Casado, Esther ^a   Cullell Young, Martin ^c   Baselga, Jose ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c PHARMAMAR S A   (Spain)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Dose escalation; ES 285; Pharmacokinetics; Phase I; Spisulosine

Indexed keywords

ANTINEOPLASTIC AGENT; ES 285; SPISULOSINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS; HUMAN; INJECTION SITE PHLEBITIS; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; TREMOR;

ADULT; AGED; ALKANES; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856510555     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9529-9     Document Type: Article

References (12)

1. Faircloth G, Cuevas C (2006) Kahalalide F and ES285: Potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363-379
2. Baird R, Clarke P, Workman P (2005) ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays. AACR Meeting Abstracts 2005(1):970
3. Sanchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, Diaz-Laviada I (2008) Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol 584(2-3):237- 245. doi:S0014-2999(08)00158-1
4. Cuadros R, Montejo de Garcini E, Wandosell F, Faircloth G, Fernandez-Sousa JM, Avila J (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 152(1):23-29. doi:S0304-3835(99)00428-0 (Pubitemid 30169014)
5. Salcedo M, Cuevas C, Alonso JL, Otero G, Faircloth G, Fernandez-Sousa JM, Avila J, Wandosell F (2007) The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 12(2):395-409. doi:10.1007/s10495- 006-0573-z (Pubitemid 46169919)
6. Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, Lopez Lazaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 8(6):1430-1437. doi:1535-7163.MCT-08-1167
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
8. Den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH (2005) Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES- 285.HCL. PDA J Pharm Sci Technol 59(4):246-257 (Pubitemid 41346134)
9. Den Brok MW, Nuijen B, Garcia JL, Miranda E, Calvo P, Manada C, Beijnen JH (2006) Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropylbeta- cyclodextrin in infusion devices. Pharmazie 61(1):21-24 (Pubitemid 43128770)
10. Stokvis E, Nan-Offeringa L, Rosing H, Lopez-Lazaro L, Acena JL, Miranda E, Lyubimov A, Levine BS, D'Aleo C, Schellens JH, Beijnen JH (2003) Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 38(5):548-554. doi:10.1002/ jms.469 (Pubitemid 36665542)
11. Salazar R, Soria J, Majem M, Ropert S, Garcia M, Armand J, Lopez Lazaro L, Escolar L, de las Heras B (2006) Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES- 285 in patients with advanced malignant solid tumors. 4th International Symposium on Targeted Anticancer Therapies. Ann Oncol 17 (S3):iii49-iii50. doi:10.1093/annonc/md1922
12. Massard C, Majem M, Soria J-C, Salazar R, Deutsch E, Garcia M, Oaknin A, Soto A, de las Heras B, Armand J-P (2007) Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous es-285 in patients with advanced malignant solid tumors. AACR Meeting Abstracts (3-Molecular-Targets-Meeting):A4